Novartis trims again with $390m drugs sale to RecordatiNovartis has been streamlining its business since CEO Vas Narasimhan took over, and has continued that push with Share XNovartis trims again with $390m drugs sale to Recordatihttps://pharmaphorum.com/news/novartis-trims-again-with-390m-drugs-sale-to-recordati/
Novartis and Amgen axe BACE drug for Alzheimer’sAnother Alzheimer’s disease drug has been axed after Novartis, Amgen and the Banner Alzheimer’s Institute decided to end Share XNovartis and Amgen axe BACE drug for Alzheimer’shttps://pharmaphorum.com/news/novartis-and-amgen-axe-bace-drug-for-alzheimers/
Under threat from Novartis, Biogen hails new data from SMA drug SpinrazaUnder threat from a gene therapy from Novartis, Biogen is making the case for its drug Spinraza for Share XUnder threat from Novartis, Biogen hails new data from SMA drug Spinrazahttps://pharmaphorum.com/news/under-threat-from-novartis-biogen-hails-new-data-from-sma-drug-spinraza/
Novartis secures initial block on Gilenya generics in USNovartis has won a temporary reprieve from generic competition to its big-selling oral multiple sclerosis therapy Gilenya in Share XNovartis secures initial block on Gilenya generics in UShttps://pharmaphorum.com/news/novartis-secures-initial-block-on-gilenya-generics-in-us/
Conatus axes staff after latest failure of Novartis-partnered NASH drugConatus has said it will have to cut around 40% of its workforce and jettison some pipeline projects Share XConatus axes staff after latest failure of Novartis-partnered NASH drughttps://pharmaphorum.com/news/conatus-axes-staff-after-latest-nash-trial-failure/
Novartis closing in on deal with US government over bribery allegationsNovartis is close to an agreement with the US government over allegations it bribed doctors to market its Share XNovartis closing in on deal with US government over bribery allegationshttps://pharmaphorum.com/news/novartis-deal-bribery-allegations/
Sanofi appoints former Novartis exec Hudson as CEOSanofi has appointed Novartis’ pharma chief Paul Hudson as chief executive to replace the retiring Olivier Brandicourt, prompting Share XSanofi appoints former Novartis exec Hudson as CEOhttps://pharmaphorum.com/news/sanofi-appoints-former-novartis-exec-hudson-as-ceo/
Novartis builds case for asthma drugs to challenge GSKNovartis has positive data for a two-drug asthma regimen that forms the backbone of its efforts to take Share XNovartis builds case for asthma drugs to challenge GSKhttps://pharmaphorum.com/news/novartis-asthma-drugs-challenge-gsk/
Novartis scores first approval for PIK3CA breast cancer drugThe FDA has approved Novartis’ breast cancer drug Piqray (alpelisib), making it the first marketed treatment targeting the Share XNovartis scores first approval for PIK3CA breast cancer drughttps://pharmaphorum.com/news/novartis-scores-first-approval-for-pik3ca-breast-cancer-drug/
